Medicinal Chemistry News and Research

RSS

Domainex Integrates Nuclera’s eProtein Discovery System to Enhance Drug Discovery Services

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, and Domainex, a multi-award winning provider of integrated, pre-clinical drug discovery services, today announced that Domainex is the first contract research organization (CRO) to have installed the eProtein Discovery system and offer protein production services using the technology.

9 Nov 2024

Fighting Drug-Resistant TB with a Novel Antibiotic

A novel semi-synthetic molecule that produces significant activity against strains of Mycobacterium tuberculosis, including those that are resistant to drugs, can be generated from natural compounds according to a study published in the American Society for Microbiology journal Microbiology Spectrum.

4 Oct 2024

Unraveling the Molecular Mechanism Behind Neocapritermes taracua's Explosive Defense

Researchers from the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, in cooperation with colleagues from the Faculty of Tropical AgriScience of the Czech University of Life Sciences in Prague, are unraveling the mysteries of the life of termites.

28 Aug 2024

Enhanced Drug Discovery with Novel Sulfur Fluoride Exchange Reagent

Researchers at the Moffitt Cancer Center have created a new reagent that improves drug production precision. This novel approach, described in Nature Communications, presents a new sulfur fluoride exchange (SuFEx) reagent that enables the highly regulated manufacture of important sulfur-based compounds such as sulfinamides, sulfonimidamides, and sulfoximines.

19 Aug 2024

Emerging Treatments and Drug Repositioning for NAFLD and NASH

The current research on drug candidates and molecular targets being clinically tested for the treatment of non-alcoholic steatohepatitis (NASH) and NAFLD.

9 Aug 2024

Drug Candidates Show Promise to Reverse HIV's Ability to Escape Immune System Detection

University of Pittsburgh School of Medicine scientists have identified drug candidates that show promise to reverse the ability of HIV to escape detection by the immune system.

20 Mar 2024

Novel Antibiotic Discovery: Harnessing Energy Compounds to Combat Bacterial Infections

About a decade ago, researchers in UC Santa Barbara chemistry professor Guillermo Bazan's lab began to observe a recurring challenge in their research: Some of the compounds they were developing to harness energy from bacteria were instead killing the microbes.

22 Feb 2024

Revolutionizing Drug Discovery with Novel Sulfur Compound Synthesis

Over the past decade, there has been significant progress in the development of novel sulfur-containing compounds utilized across diverse industries, including pharmaceuticals and agricultural products.

23 Jan 2024

AI-Powered Drug Breakthrough: Insilico Unveils Potent FGFR2/3 Inhibitor for Solid Tumors

Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

29 Dec 2023

Biomedical Publisher Future Science Group Joins Taylor & Francis

Taylor & Francis’ Support for Scientific and Medical Communities Expanded with Journals, Digital Hubs and Publishing Solutions

5 Dec 2023

New Breakthrough in Generative AI Models and AlphaFold Structures for Drug Discovery

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

3 Aug 2023

Analyzing DNA Damage-Induced NF-κB Targeted by Novel Small Molecule Inhibitors

Chemotherapy and radiotherapy aim to destroy cancer cells by inducing DNA double-strand breaks – damage that, once inflicted, usually causes the cells to die. But damage to a cell's genetic material also activates a signaling pathway called IKK/NF-κB that helps prevent cell death, thus limiting the success of these treatments in patients.

28 Jul 2023

New Collaboration Aims to Advance Cancer Therapies Against Previously Undruggable Targets

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns the innovative technology and capabilities of each organization at the earliest stages of drug discovery and development to rapidly advance impactful new cancer therapies against previously undruggable targets.

26 Jul 2023

Discovery of Shanghai APP Mutation Offers New Avenues for Treatment of Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia.

15 May 2023

Discovering Novel Senolytic Compounds with the Power of Artificial Intelligence

A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer.

8 May 2023

Novel framework provides solutions to evade detoxification networks

Scientists at St. Jude Children's Research Hospital have demonstrated how drug makers can avoid two key problems: toxicity and resistance. The researchers made slight changes to a small molecule to reduce its metabolism and elimination by the cellular detoxification network regulated by the pregnane X receptor (PXR). This research provides a framework to develop solutions to the long-standing issue of how to evade detoxification networks using medicinal chemistry. The findings were published today in Proceedings of the National Academy of Sciences.

1 Mar 2023

Developing a potential drug molecule that targets STAT5

STAT5 has generally been recognized as an enticing cancer target, but after years of research, it was downgraded to the “undruggable” category. Now, scientists at the University of Michigan Rogel Cancer Center have achieved success with a novel approach.

17 Feb 2023

An innovative strategy for on-demand contraception for men

An experimental contraceptive drug developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models. The study, published in Nature Communications on Feb. 14, demonstrates that an on-demand male contraceptive is possible.

16 Feb 2023

New family of pharmaceutical compounds that target RNA

In Jennifer Hines’ lab, a group of graduate and undergraduate chemistry students recently discovered a new family of compounds that can target RNA and interfere with its function. In the future, RNA-targeted treatments to treat cancer and metabolic diseases, together with bacterial and viral infections, could be developed using the chemical scaffold found in this research.

15 Feb 2023

Researchers develop a sustainable two-step process to upcycle organic carbon waste

When nature designed lignin -; the fibrous, woody material that gives plants their rigid structure -; it didn't cut any corners. Incredibly slow to break down, lignin is so sturdy and long lasting that it is resistant to bacteria and rot.

1 Feb 2023